* Avenue Therapeutics Inc is expected to report results on August 8 (estimated) for the period ending June 30 2024
*
* LSEG's mean analyst estimate for Avenue Therapeutics Inc is for a loss of $1.05 per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Avenue Therapeutics Inc is $12.00, above its last closing price of $2.57.
This summary was machine generated August 6 at 12:56 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments